ResMed muted ahead of next earnings, shares trade steadily on NYSE

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-28, 09:40.

ResMed Inc. (US7611521078) is in a calm phase on the NYSE as investors look ahead to its next quarterly earnings update. The company last reported fiscal third-quarter results on April 25, 2024, and typically follows a regular July earnings pattern according to its historical calendar.

How ResMed last reported

In its most recent fiscal third-quarter release for the period ended March 31, 2024, ResMed posted revenue of 1.2 billion dollars, up around 7 percent year on year according to the company’s investor materials. Net income attributed to ResMed reached approximately 270 million dollars in the same quarter, reflecting solid profitability in its core sleep and respiratory care business.

The shares trade on the NYSE under the ticker RMD alongside other large US medtech names such as Medtronic and Boston Scientific, giving international investors a clear sector peer context.

Analyst views and sector context

Covering analysts on MarketBeat show a consensus leaning toward positive on the ResMed stock, with several brokerages maintaining Buy or Overweight ratings and a range of price targets above the recent trading band. The firm is generally seen as a structural beneficiary of long-term trends in sleep apnea diagnosis and home respiratory care, an assessment that underpins many analyst models.

ResMed’s valuation is compared regularly with US medtech peers including Dexcom and Intuitive Surgical, where growth and margin trajectories are watched closely by Wall Street research desks.

How the company makes money

ResMed generates most of its revenue from devices and software used to diagnose and treat sleep-disordered breathing, notably obstructive sleep apnea. A representative product line is its AirSense series of positive airway pressure devices, which are often paired with masks and cloud-connected monitoring solutions sold to patients via sleep clinics and homecare providers.

Where the stock trades today

ResMed shares (US7611521078) most recently traded at around 200 dollars on the NYSE in late June 2026, based on MarketBeat price data, with the quote reflecting regular-session levels in US dollars.

Disclaimer: This article is for informational purposes only and does not contain investment advice, recommendations or price targets. All data are based on publicly available sources and may change without notice.